Cargando…

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAF(V600E) metastatic melanoma. However, resistance to such compounds represents a formidable problem. Using whole-exome sequencing and functional analyses, we have investigated the nature and ple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kemper, Kristel, Krijgsman, Oscar, Cornelissen-Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, Song, Ji-Ying, Kuilman, Thomas, Vis, Daniel J, Wessels, Lodewyk F, Voest, Emile E, Schumacher, Ton NM, Blank, Christian U, Adams, David J, Haanen, John B, Peeper, Daniel S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568946/ https://www.ncbi.nlm.nih.gov/pubmed/26105199 http://dx.doi.org/10.15252/emmm.201404914

Ejemplares similares

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts
por: Kemper, Kristel, et al.
Publicado: (2016)

XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data
por: Kluin, Roelof J. C., et al.
Publicado: (2018)

Cancer Drug Addiction is Relayed by an ERK2-Dependent Phenotype Switch
por: Kong, Xiangjun, et al.
Publicado: (2017)

CopywriteR: DNA copy number detection from off-target sequence data
por: Kuilman, Thomas, et al.
Publicado: (2015)

Phenotypic diversity drives paracrine drug tolerance
por: Kuilman, Thomas, et al.
Publicado: (2017)

Large variety in a panel of human colon cancer organoids in response to EZH2 inhibition
por: Koppens, Martijn AJ, et al.
Publicado: (2016)

Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival
por: Iskit, Sedef, et al.
Publicado: (2015)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

Complete remission of critical neurohistiocytosis by vemurafenib
por: Euskirchen, Philipp, et al.
Publicado: (2015)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
por: Wolf, Sanne EJ, et al.
Publicado: (2013)

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study
por: van der Hiel, Bernies, et al.
Publicado: (2017)

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
por: Kim, Yongsoo, et al.
Publicado: (2019)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response
por: Ibáñez-Molero, Sofía, et al.
Publicado: (2022)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma
por: Theelen, W. S. M. E., et al.
Publicado: (2020)

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
por: de Haan, Jorine, et al.
Publicado: (2018)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts
por: Acciardo, Stefania, et al.
Publicado: (2019)

Integrative epigenetic taxonomy of primary prostate cancer
por: Stelloo, Suzan, et al.
Publicado: (2018)

A 3D human co-culture to model neuron-astrocyte interactions in tauopathies
por: Batenburg, Kevin L., et al.
Publicado: (2023)

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer
por: Gallenne, Tristan, et al.
Publicado: (2017)

Targeting MEK in vemurafenib-resistant hairy cell leukemia
por: Caeser, Rebecca, et al.
Publicado: (2018)

EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
por: Pietersen, Alexandra M, et al.
Publicado: (2008)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Delayed-onset vemurafenib-induced panniculitis
por: Vance, Stephen L., et al.
Publicado: (2017)

A Rare Cause of Uveitis: Vemurafenib
por: Sızmaz, Selçuk, et al.
Publicado: (2018)

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer
por: Iskit, Sedef, et al.
Publicado: (2016)

RNF31 inhibition sensitizes tumors to bystander killing by innate and adaptive immune cells
por: Zhang, Zhengkui, et al.
Publicado: (2022)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer
por: Theelen, Willemijn S. M. E., et al.
Publicado: (2019)

Cancer genome: highlights of a Nature Medicine perspective
por: Voest, Emile
Publicado: (2016)

Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts
por: Lee, Woan-Ruoh, et al.
Publicado: (2015)

Development of [(11)C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts
por: Slobbe, Paul, et al.
Publicado: (2017)

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study
por: Donadieu, Jean, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_kpck477v0td8l5puo414m3q7el